IL-2 Variant Modulation for Selective Treg Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for novel IL-2-based agents that are safe and efficacious for treating diseases, as existing IL-2 therapies are limited by severe toxicity and only benefit a small subset of eligible patients.
Innovation Solution
Development of IL-2 agents with specific amino acid alterations that stabilize the protein, reduce affinity for CD122, and maintain or reduce affinity for CD25, thereby enhancing regulatory T cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type IL-2 is used for therapy, then immune system regulation and disease treatment efficacy are achieved, but severe toxicity occurs including fever, nausea, vomiting, vascular leak, and hypotension
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions at particular positions in the IL-2 molecule (e.g., positions 35, 38, 42, 68, 74, 84, 87, 92, 126) to selectively modify its interaction with different IL-2 receptors. This allows the modified IL-2 to have differentiated binding characteristics - reduced affinity for CD122 while maintaining or reducing affinity for CD25 - thereby achieving selective enhancement of Treg activity while reducing toxic side effects associated with broad immune activation
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequence of IL-2 through multiple substitution mutations. These mutations alter the biophysical and biochemical parameters of the IL-2 molecule, including its binding affinity constants (KD values) for different receptors, its stability, and its half-life in circulation. The cumulative effect of these parameter changes creates a modified IL-2 with a shifted pharmacological profile that favors Treg expansion while minimizing toxicity
2Productivity
If IL-2 therapy is administered, then T cell proliferation and immune response are enhanced, but the treatment is restricted to a small subset of eligible patients due to severe toxicity
Solution Approach 1:
The modified IL-2 agents exhibit local quality through selective receptor binding preferences. By reducing affinity for CD122 (expressed on NK cells and some T cells) while maintaining or reducing affinity for CD25 (overexpressed on Tregs), the patent creates an IL-2 variant that selectively targets Treg cells. This selective action expands the patient eligibility pool by treating autoimmune and inflammatory conditions without the severe toxicities that previously limited therapy to a small subset of patients
Solution Approach 2:
The patent converts the harmful overactivation of immune responses into a beneficial selective modulation. Instead of broadly stimulating all IL-2-responsive cells (which causes toxicity), the modified IL-2 agents are designed to preferentially activate Treg cells, transforming the potential harm of immune overstimulation into the benefit of targeted immunosuppression for autoimmune diseases
Data Source
AI summary
IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.